Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.11 USD | -3.54% | +4.98% | -19.92% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.92% | 49.02M | D+ | ||
+14.78% | 79.51B | B- | ||
+6.49% | 50.92B | B+ | ||
+1.35% | 48.11B | B | ||
+6.55% | 39.71B | B+ | ||
+19.34% | 37.78B | B | ||
+2.84% | 30.07B | B | ||
-7.77% | 27.56B | B- | ||
-18.42% | 24.71B | A- | ||
+6.89% | 21.99B | A |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NEUE Stock
- Ratings NeueHealth, Inc.